CA2432428C - Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them - Google Patents

Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them Download PDF

Info

Publication number
CA2432428C
CA2432428C CA002432428A CA2432428A CA2432428C CA 2432428 C CA2432428 C CA 2432428C CA 002432428 A CA002432428 A CA 002432428A CA 2432428 A CA2432428 A CA 2432428A CA 2432428 C CA2432428 C CA 2432428C
Authority
CA
Canada
Prior art keywords
amino
quinazoline
buten
oxo
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002432428A
Other languages
French (fr)
Other versions
CA2432428A1 (en
Inventor
Frank Himmelsbach
Elke Langkopf
Stefan Blech
Birgit Jung
Anke Baum
Flavio Solca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7667887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2432428(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2432428A1 publication Critical patent/CA2432428A1/en
Application granted granted Critical
Publication of CA2432428C publication Critical patent/CA2432428C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to quinazoline derivatives of general formula (see formula I) wherein R a, R b and R c are defined as in claim 1, the tautomers, the stereoisomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.

Description

Boehringer Ingelheim Pharma KG Case 5/1310-Ro D-55216 Ingelheim/Rhein foreign filing text 74703fft.204 Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them The present invention relates to quinazoline derivatives of general formula Ra 11'~ NH

N ~ ~ N \ Rb ~ (I), o N Rc the tautomers, the stereoisomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract, and the preparation thereof.

In the above general formula I

Ra denotes a benzyl, 1-phenylethyl or 3-chloro-4-fluorophenyl group, ~. Rb denotes a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)-amino, N-ethyl-N-(2-methoxyethyl)-amino, bis-(2-methoxyethyl)-amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)-amino, N-methyl-N-(tetrahydrofuran-2-yl-methyl)-amino, N-methyl-N-(tetrahydrofuran-3-yl-methyl)-amino, N-methyl-N-(tetrahydropyran-4-yl)-amino or N-methyl-N-(tetrahydropyran-4-yl-methyl)-amino group and R, denotes a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yl-oxy, tetrahydrofuran-2-yl-methoxy, tetrahydrofuran-3-yl-methoxy, tetrahydropyran-4-yl-oxy or tetrahydropyran-4-yl-methoxy group, with the exception of the compounds (1) 3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, (2) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, (3) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, 1 o (4) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxy-quinazoline, (5) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, (6) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxy-quinazoline, (7) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-2 0 cyclopentyloxy-quinazoline, (8) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxy-quinazoline, (9) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yi)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, (10) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, (11) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(diethylarnino)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxy-quinazoline, (12) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-3 5 cyclopentyloxy-quinazoline, (13) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, (14) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[bis-(2-methoxyethyl)-amino]-1-oxo-2-buten-l-yI}amino)-7-cyclopropylmethoxy-quinazoline, (15) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-ethyl-N-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (16) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydropyran-4-yl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (17) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-l-yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, (18) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-l-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, (19) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-f/+o4rohvrlrnnvr~n-A-vllnvvl-ni linaznlino i~.,... y.... r,y.~.. ~.,,.,I M.....~. ., (20) 4-[(3-chloro-4-fiuorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydrofuran-2-yl-methyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline and (21) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydrofuran-3-yl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline.

- 3a -According to one aspect of the present invention, there is provided a compound of general formula:

Ra ,, NH
H
N
N Rb O
N R

wherein Ra denotes a 1-phenylethyl or a 3-chloro-4-fluorophenyl group, Rb denotes a dimethylamino group and Rc denotes a tetrahydrofuran-3-yl-oxy, tetrahydrofuran-2-yl-methoxy, tetrahydro-furan-3-yl-methoxy, tetrahydropyran-4-yl-oxy or tetrahydropyran-4-yl-methoxy group, or a tautomer, a stereoisomer or a salt thereof.

Preferred compounds of the above general formula I are those wherein Ra, Rb and R, are as hereinbefore defined, but with the exception of the compounds (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, (2) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, (3) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(dimethyiamino)-1-oxo-2-buten-1-yl]amino)-7-cyclopropylmethoxy-quinazoline, (4) 4-[(3-chioro-4-fiuorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxy-quinazoline, (5) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, (6) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxy-quinazoline, (7) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, (8) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-2 0 cyclobutyloxy-quinazoline, (9) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, (10) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yI]amino}-7-cyclopentyloxy-quinazoline, (11) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxy-quinazoline, (12) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, (13) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-3 5 cyclopropylmethoxy-quinazoline, (14) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[bis-(2-methoxyethyl)-amino]-1-oxo-2-buten-l-yI}amino)-7-cyclopropylmethoxy-quinazoline, (15) 4-[(3-chloro-4-fluorophenyi)amino]-6-({4-[N-ethyl-N-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (16) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydropyran-4-yl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (17) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-l-yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, (18) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, (19) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yI]amino}-7-[(tetrahydropyran-4-yl)oxy]-quinazoline, (20) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydrofuran-2-yl-methyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (21) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydrofuran-3-yl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (22) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxyethyl)-N-methylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (23) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[bis-(2-methoxyethyl)-amino]-1-oxo-2-buten-l-3 0 yI}amino)-7-cyclobutyloxy-quinazoline, (24) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxy-quinazoline, (25) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[(S)-N-methyl-N-(tetrahydrofuran-3-yl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxy-quinazoline, (26) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[(R)-N-methyl-N-(tetrahydrofuran-3-yl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxy-quinazoline, (27) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydropyran-4-yl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxy-quinazoline, (28) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[(R)-N-methyl-N-(tetrahydrofuran-2-ylmethyl)-amino]-1-oxo-2-buten-1-yl}-amino)-7-cyclobutyloxy-quinazoline, (29) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[(S)-N-methyl-N-(tetrahydrofuran-2-ylmethyl)-amino]-1-oxo-2-buten-1-yl}-amino)-7-cyclobutyloxy-quinazoline, (30) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-(tetrahydrofuran-3-yl-oxy)-quinazoline, (31) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}arnino)-7-(tetrahydropyran-4-yl-oxy)-quinazoline, (32) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-(tetrahydrofuran-2-yi-methoxy)-quinazoline and 2 5 (33) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, the tautomers, the stereoisomers and the salts thereof.

Particularly preferred compounds of general formula I are those wherein Ra denotes a 1-phenylethyl or 3-chloro-4-fluorophenyl group, Rb denotes a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)-amino, N-ethyl-N-(2-methoxyethyl)-amino, bis-(2-methoxyethyl)-amino, morpholino, N-methyi-N-(tetrahydrofuran-3-yl)-amino, N-methyl-N-(tetrahydrofuran-2-yl-methyl)-amino, N-methyl-N-(tetrahydrofuran-3-yi-methyl)-amino, N-methyl-N-(tetrahydropyran-4-y1)-amino or N-methyl-N-(tetrahydropyran-4-yl-methyl)-amino group and R, denotes a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yi-oxy, tetrahydrofuran-2-yi-methoxy, tetra hyd rofu ran-3-yl-m eth oxy, tetrahydropyran-4-yl-oxy or tetrahydropyran-4-yl-methoxy group, with the exception of the compounds (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, (2) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, (3) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(dimethylamino)-1-oxo-2-buten-1-yi]amino}-7-cyclopropylmethoxy-quinazoline, (4) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxy-quinazoline, (5) 4-[(3-chloro-4-fluorophenyl)arnino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-2 5 cyclopentyloxy-quinazoline, (6) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxy-quinazoline, (7) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, (8) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxy-quinazoline, (9) 4-[(R)-(1-phenyl-ethyi)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopropyimethoxy-quinazoline, (10) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, (11) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxy-quinazoline, (12) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-l-yi]arnino}-7-cyclopentyloxy-quinazoline, (13) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, (14) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[bis-(2-methoxyethyl)-amino]-1-oxo-2-buten-l-yI}amino)-7-cyclopropylmethoxy-quinazoline, (15) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-ethyl-N-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (16) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydropyran-4-yl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (17) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, (18) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-l-yI]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline, (19) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(diethylamino)-1-oxo-2-buten-l-yl]amino}-7-[(tetrahydropyran-4-yl)oxy]-quinazoline, (20) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydrofuran-3-yl)-arnino]-1-oxo-2-buten-1-yl}arnino)-7-cyclopropylmethoxy-quinazoline, (21) 4-[(3-chloro-4-fiuorophenyl)amino]-6-({4-[N-(2-methoxyethyl)-N-methylamino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (22) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[bis-(2-methoxyethyl)-amino]-1-oxo-2-buten-l-yI}amino)-7-cyclobutyloxy-quinazoline, (23) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxy-quinazoline, (24) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[(S)-N-methyl-N-(tetrahydrofuran-3-yl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxy-quinazoline, (25) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[(R)-N-methyl-N-(tetrahydrofuran-3-yl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxy-quinazoline, (26) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydropyran-4-yl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclobutyloxy-quinazoline, (27) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-(tetrahydrofuran-3-yl-oxy)-quinazoline, (28) 4-[(3-chIoro-4-fluoropheny1)amino]-6-({4-[N-methyl-N-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-(tetrahydropyran-4-yl-oxy)-quinazoline, (29) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(2-methoxyethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-(tetrahydrofuran-2-yl-methoxy)-quinazoline, (30) 4-[(3-chloro-4-fiuorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-3 o buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline, (31) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-methyl-N-(tetrahydrofuran-2-yl-methyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (32) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[(R)-N-methyl-N-(tetrahydrofuran-2-ylmethyl)-amino]-1-oxo-2-buten-1-yl}-amino)-7-cyclobutyloxy-quinazoline and (33) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[(S)-N-methyl-N-(tetrahydrofuran-2-ylmethyl)-amino]-1-oxo-2-buten-1-yl}-amino)-7-cyclobutyloxy-quinazoline, the tautomers, the stereoisomers and the salts thereof.

The following particularly preferred compounds of general formula I may be mentioned by way of example:

a 4- 3-chloro-4-fluoro hen I amino 6- 4-N,N-dimeth lamino 1-oxo-2-buten-1-YI]amino ( ) [( p Y ) l-{[ ( Y )- }-7-cyclobutyloxy-quinazoline, (b) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline, (c) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(N,N-bis-(2-methoxy-ethyl)-amino)-1-oxo-2-buten-l-yl]arn ino}-7-cyclopropylmethoxy-quinazoline, (d) 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-ethyl-amino]-1-oxo-2-buten-l-yl}amino)-7-cyclopropylmethoxy-quinazoline, (e) 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-rnethyl-amino]-1-oxo-2-buten-2 5 1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (f) 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (g) 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(tetrahydrofuran-3-yl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline, (h) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{N-[(tetrahydrofuran-3-yl)methyl]-N-rnethyl-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline, (i) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yI]amino}-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline, (j) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, (k) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-buten-1-yI]amino}-7-(tetrahydropyran-4-yloxy)-quinazoline, (I) 4-[(3-chloro-4-fiuorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-l-yI]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, (m) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yI]amino}-7-[(tetrahydrofuran-3-yl)methoxy]-quinazoline, (o) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N, N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahydrofuran-3-yl)methoxy]-quinazoline, (p) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yI]amino}-7-cyclopropylmethoxy-quinazoline, (q) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N, N-bis-(2-methoxy-ethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, (r) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(rnorpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline, (s) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline and (t) 4-[(3-chloro-4-fluorophenyl)arnino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-l-yl]amino}-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline, the tautomers, the stereoisomers and the salts thereof.

The compounds of general formula I may be prepared by the following methods, for example:

a) reacting a compound of general formula Ra -~- NH

N Rc wherein Ra and Rc are as hereinbefore defined, with a compound of general formula Z' \ (IIl), Rb wherein Rb is as hereinbefore defined and Z, denotes a leaving group such as a halogen atom, e.g. a chlorine or bromine atom, or a hydroxy group.
The reaction is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, optionally in the presence of an inorganic or organic base and optionally in the presence of a dehydrating agent, expediently at temperatures between -50 and 150 C, preferably at temperatures between -20 and 80 C.

With a compound of general formula III wherein Z, denotes a leaving group, the reaction is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, conveniently in the presence of a tertiary organic base such as triethylamine, pyridine or 4-dimethylaminopyridine, in the presence of N-ethyl-diisopropylamine (Hunig base), whilst these organic bases may simultaneously also act as solvent, or in the presence of an inorganic base such as sodium carbonate, potassium carbonate or sodium hydroxide solution, expediently at temperatures between -50 and 150 C, preferably at temperatures between -20 and 80 C.

With a compound of general formula III wherein Z, denotes a hydroxy group, the reaction is preferably carried out in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, thionyl chloride, trimethyl chlorosilane, phosphorus trichioride, phosphorus pentoxide, hexamethyldisilazane, N,N'-dicyclohexylcarbodiimide, N, N'-dicyclohexylcarbodiimide/N-hydroxysuccinirnide, 1-hydroxy-benzotriazole, N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, expediently in a solvent such as methylene chloride, tetrahydrofuran, dioxane, toluene, chlorobenzene, dimethylformamide, dimethylsulphoxide, ethylene glycol diethylether or sulpholane and optionally in the presence of a reaction accelerator such as 4-dimethylaminopyridine at temperatures between -50 and 150 C, but preferably at temperatures between -20 and 80 C.
b) Reacting a compound of general formula Ra I" NH

N ~ Z2 I (IV), `~ 0 N \ Rc wherein R. and Rc are as hereinbefore defined and Z2 denotes a leaving group such as a halogen atom, a substituted hydroxy or sulphonyloxy group such as a chlorine or bromine atom, a methanesulphonyloxy or p-toluenesulphonyloxy group, with a compound of general formula H - Rb (V), wherein Rb is as hereinbefore defined.

The reaction is expediently carried out in a solvent such as isopropanol, butanol, tetrahydrofuran, dioxane, toluene, chlorobenzene, dimethylformamide, dimethylsulphoxide, methylene chloride, ethylene glycol monomethylether, ethylene glycol diethylether or sulpholane or mixtures thereof, optionally in the presence of an inorganic or tertiary organic base, e.g. sodium carbonate or potassium hydroxide, a tertiary organic base, e.g.

triethylamine or N-ethyl-diisopropylamine (Hunig base), whilst these organic bases may simultaneously also serve as solvent, and optionally in the presence of a reaction accelerator such as an alkali metal halide at temperatures between -20 and 150 C, but preferably at temperatures between -10 and 100 C. The reaction may, however, also be carried out without a solvent or in an excess of the compound of general formula V used.

In the reactions described above, the secondary amino group bound to the quinazoline of general formula II or IV may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction. Examples of protecting groups include the formyl, acetyl, trifluoroacetyl, ethoxycarbonyl, tert. butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group.

Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide or aprotically, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 C, preferably at temperatures between 10 and 100 C.

However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 C, but preferably at ambient temperatures between 20 and 60 C, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar. A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisole.

A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid or by treating with iodotrimethylsilane, optionally using a solvent such as methylene chloride, dioxane, methanol or diethyl ether.

A trifluoroacetyl group is preferably cleaved by treating with an acid such as hydrochloric acid, optionally in the presence of a solvent such as acetic acid at temperatures between 50 and 120 C or by treating with sodium hydroxide solution optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50 C.

Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers, as mentioned hereinbefore. Thus, for example, cis/trans mixtures may be resolved into their cis and trans isomers, and compounds with at least one optically active carbon atom may be separated into their enantiomers.
Thus, for example, the cis/trans mixtures obtained may be resolved by chromatography into the cis and trans isomers thereof, the compounds of general formula I obtained which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.
The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents.
Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+) or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)-or (-)-menthyloxycarbonyl.
Furthermore, the compounds of formula I obtained may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulphonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.

The compounds of general formulae II to V used as starting materials are known from the literature in some cases or may be obtained by methods known from the literature.

ti For example, a starting compound of general formula II is obtained by reacting a 7-fluoro-6-nitro compound correspondingly substituted in the 4 position with a corresponding alkoxide and subsequently reducing the nitro compound thus obtained or a starting compound of general formula III is obtained, for example, by reacting a suitable bromocrotonic acid derivative with one of the amines of general formula V
known from the literature, or a starting compound of general formula IV is obtained by acylating a compound of general formula II with a suitable crotonic acid derivative.

As already mentioned hereinbefore, the compounds of general formula I
according to the invention and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by the Epidermal Growth Factor receptor (EGF-R), whilst this may be achieved for example by inhibiting ligand bonding, receptor dimerisation or tyrosine kinase itself. It is also possible to block the transmission of signals to components located further down.

The biological properties of the new compounds were investigated as follows:

The inhibition of human EGF-receptor kinase was determined using the cytoplasmic tyrosine kinase domain (methionine 664 to alanine 1186, based on the sequence published in Nature 309 (1984), 418). To do this, the protein was expressed in Sf9 insect cells as a GST fusion protein using the Baculovirus expression system.

The enzyme activity was measured in the presence or absence of the test compounds in serial dilutions. The polymer pEY (4:1) produced by SIGMA was used as the substrate.
Biotinylated pEY (bio-pEY) was added as the tracer substrate. Every 100 NI of reaction solution contained 10 pl of the inhibitor in 50% DMSO, 20 pl of the substrate solution (200 mM HEPES pH 7.4, 50 mM magnesium acetate, 2.5 mg/mI poly(EY), 5 pg/mI bio-pEY) and 20 NI of enzyme preparation. The enzyme reaction was started by the addition of 50N1 of a 100NM ATP solution in 10 mM magnesium chloride. The dilution of the enzyme preparation was adjusted so that the incorporation of phosphate into the bio-pEY was linear in terms of time and quantity of enzyme. The enzyme preparation was diluted in 20 mM HEPES
pH 7.4, 1 mM EDTA, 130 mM common salt, 0.05% Triton X-100, 1 mM DTT and 10% glycerol.

The enzyme assays were carried out at ambient temperature over a period of 30 minutes and were ended by the addition of 50 NI of a stopping solution (250 mM EDTA in 20 mM
HEPES pH 7.4). 100 NI were placed on a streptavidin-coated microtitre plate and incubated for 60 minutes at ambient temperature. Then the plate was washed with 200 pl of a washing solution (50 mM Tris, 0.05% Tween 20). After the addition of 100 pl of a HRPO-labelled anti-PY antibody (PY20H Anti-PTyr:HRP produced by Transduction Laboratories, 250 ng/ml) it 1.0 was incubated for 60 minutes. Then the microtitre plate was washed three times with 200 pl of washing solution. The samples were then combined with 100 NI of a TMB-peroxidase solution (A:B = 1:1, Kirkegaard Perry Laboratories). After 10 minutes the reaction was stopped. The extinction was measured at OD45onm with an ELISA reader. All data points were measured three times.
The data were matched by means of an iterative calculation using an analytical programme for sigmoidal curves (Graph Pad Prism Version 3.0) with variable Hill pitch.
All the iteration data released showed a correlation coefficient of more 0.9 and the upper and lower values of the curves showed a spread of at least a factor of 5. The concentration of active substance which inhibits the activity of EGF-receptor kinase by 50% (IC5o) was derived from the curves.
The following results were obtained:

i 4 Compound Inhibition of EGF-(Example No.) receptor kinase IC50 [nM]
1 0.7 1(2) 0.6 1(3) 4.0 1(5) 3.0 1(10) 0.5 1(22) 1.0 1(32) 0.3 1(33) 0.5 1(34) 0.4 The compounds of general formula I according to the invention thus inhibit signal transduction by tyrosine kinases, as demonstrated by the example of the human EGF
receptor, and are therefore useful for treating pathophysiological processes caused by hyperfunction of tyrosine kinases. These are e.g. benign or malignant tumours, particularly tumours of epithelial and neuroepithelial origin, metastasisation and the abnormal proliferation of vascular endothelial cells (neoangiogenesis).

1.o The compounds according to the invention are also useful for preventing and treating diseases of the airways and lungs which are accompanied by increased or altered production of mucus caused by stimulation by tyrosine kinases, e.g. in inflammatory diseases of the airways such as chronic bronchitis, chronic obstructive bronchitis, asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, a1-antitrypsin deficiency, or coughs, pulmonary emphysema, pulmonary fibrosis and hyperreactive airways.

The compounds are also suitable for treating diseases of the gastrointestinal tract and bile duct and gall bladder which are associated with disrupted activity of the tyrosine kinases, such as may be found e.g. in chronic inflammatory changes such as cholecystitis, Crohn's disease, ulcerative colitis, and ulcers in the gastrointestinal tract or such as may occur in diseases of the gastrointestinal tract which are associated with increased secretions, such as Menetrier's disease, secreting adenomas and protein loss syndrome.

In addition, the compounds of general formula I and the physiologically acceptable salts thereof may be used to treat other diseases caused by abnormal function of tyrosine kinases, such as e.g. epidermal hyperproliferation (psoriasis), inflammatory processes, diseases of the immune system, hyperproliferation of haematopoietic cells, etc.
By reason of their biological properties the compounds according to the invention may be used on their own or in conjunction with other pharmacologically active compounds, for example in tumour therapy, in monotherapy or in conjunction with other anti-tumour therapeutic agents, for example in combination with topoisomerase inhibitors (e.g.
etoposide), mitosis inhibitors (e.g. vinblastine), compounds which interact with nucleic acids (e.g. cis-platin, cyclophosphamide, adriamycin), hormone antagonists (e.g.
tamoxifen), inhibitors of metabolic processes (e.g. 5-FU etc.), cytokines (e.g.
interferons), antibodies, etc.
For treating respiratory tract diseases, these compounds may be used on their own or in conjunction with other therapeutic agents for the airways, such as substances with a secretolytic, broncholytic and/or anti-inflammatory activity. For treating diseases in the region of the gastrointestinal tract, these compounds may also be administered on their own or in conjunction with substances having an effect on motility or secretion. These combinations may be administered either simultaneously or sequentially.

2 o These compounds may be administered either on their own or in conjunction with other active substances by intravenous, subcutaneous, intramuscular, intraperitoneal or intranasal route, by inhalation or transdermally or orally, whilst aerosol formulations are particularly suitable for inhalation.

For pharmaceutical use the compounds according to the invention are generally used for warm-blooded vertebrates, particularly humans, in doses of 0.01-100 mg/kg of body weight, preferably 0.1-15 mg/kg. For administration they are formulated with one or more conventional inert carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, stearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof in conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions, solutions, sprays or suppositories.

The following Examples are intended to illustrate the present invention without restricting it:

Preparation of the starting compounds:

Example I

3-methylamino-tetrahydrofuran 3.43 g of lithium aluminium hydride are added batchwise to 50 ml of tetrahydrofuran while cooling with an ice bath. Then a solution of 5.00 g of 3-[(benzyloxycarbonyl)amino]-tetrahydrofuran in 20 ml tetrahydrofuran is added dropwise, while the temperature remains below 10 C. After 10 minutes the cooling bath is removed and the reaction mixture is 1 o refluxed for about three hours. For working up, 3.7 ml of water, 3.7 ml of 15% sodium hydroxide solution and another 3 mi of water are carefully added dropwise to the reaction mixture while cooling with an ice bath. Then some tetrahydrofuran is added and the mixture is stirred for another 15 minutes. The aluminium hydroxide slurry precipitated is suction filtered and washed with a total of 150 ml of tetrahydrofuran. The filtrate is evaporated down using the rotary evaporator. A colouriess oil remains, which is reacted without any further purification.
Mass spectrum (ESI+): m/z = 102 [M+H]' Rf value: 0.20 (silica gel, methylene chloride/methanol = 9:1) 2 0 Example 11 3-f (benzyloxycarbonvl)amino]-tetrahydrofuran 12.36 ml of tetrahydrofuran-3-carboxylic acid and 27.84 ml of diphenylphosphorylazide in 500 ml of dioxane are combined with 41.91 g of benzyl alcohol and 35.81 ml of triethylamine.
The reaction mixture is heated to 100 C for about seven hours. After cooling to ambient temperature, the reaction mixture is evaporated down using the rotary evaporator. The residue is taken up in 500 ml of methylene chloride and washed twice with 100 ml of 1 N
sodium hydroxide solution. The organic phase is dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with cyclohexane/ethyl acetate (3:1 to 1:2) as eluant.
Yield: 15.60 g(55 % of theory) Mass spectrum (ESI"): m/z = 220 [M-H]"
Rf value: 0.78 (silica gel, methylene chloride/methanol = 9:1) I y Example III

6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline A mixture of 12.80 g of 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline, 200 ml of ethanol, 100 mi of water and 17.20 ml of glacial acetic acid is heated to reflux temperature. Then a total of 7.00 g of iron powder is added in batches. The reaction mixture is refluxed for about four hours and then cooled to ambient temperature overnight. For working up, the reaction mixture is evaporated using the rotary evaporator.
The residue is taken up in methylene chloride/methanol (9:1), mixed with 20 ml of concentrated ammonia solution and filtered through a layer of silica gel. It is washed with copious amounts of methylene chloride/methanol (9:1) and the combined filtrates are evaporated down. The residue is stirred with diethylether and suction filtered.
Yield: 8.59 g (73 % of theory) Mass spectrum (ESI-): m/z = 373, 375 [M-H]"
Rf value: 0.27 (silica gel, ethyl acetate/methanol = 9:1) The following compounds are obtained analogously to Example III:

(1) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline Mass spectrum (ESI"): m/z = 373, 375 [M-H]"
Rf value: 0.27 (silica gel, ethyl acetate/methanol = 9:1) (2) 6-Am in o-4-[(3-ch loro-4-fl uorophenyl) am in o]-7-(tetrahyd ropy ran-4-yloxy)-q u in azoli ne Mass spectrum (ESI"): m/z = 387, 389 [M-H]' Rf value: 0.20 (silica gel, ethyl acetate) (3) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI"): m/z = 387, 389 [M-H]"
Rf value: 0.55 (silica gel, ethyl acetate/methanol = 9:1) (4) 6-Amino-4-[(3-chloro-4-fluorophenyi)amino]-7-[(tetrahydrofuran-3-yl)methoxy]-quinazoline Mass spectrum (ESI"): m/z = 387, 389 [M-H]-Rf value: 0.40 (silica gel, ethyl acetate/methanol = 9:1) Example IV

4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline 13.80 g of potassium tert. butoxide are added batchwise to a solution of 10.80 g of (R)-3-hydroxy-tetrahydrofuran in 100 ml of N,N-dimethylformamide while cooling with an ice bath.
The reaction mixture is stirred for about one hour, then 10.40 g of 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-fluoro-quinazoline are added batchwise. The cooling bath is then removed and the deep red reaction mixture is stirred for two hours at ambient temperature. For working up the reaction mixture is poured onto about 500 ml of water and neutralised with 2 N hydrochloric acid. The yellowish precipitate formed is suction filtered and dried at 70 C in a circulating air drier.
Yield: 12.80 g Melting point: 244 C
Mass spectrum (ESI'): m/z = 403, 405 [M-H]"
The following compounds are obtained analogously to Example IV:

(1) 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline Mass spectrum (ESI"): m/z = 403, 405 [M-H]"
2 0 Rf value: 0.45 (silica gel, ethyl acetate) (2) 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-(tetrahydropyran-4-yloxy)-quinazoline Mass spectrum (ESI"): m/z = 417, 419 [M-H]"
Rf value: 0.42 (silica gel, ethyl acetate) (3) 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI-): m/z = 417, 419 [M-H]"
Rf value: 0.47 (silica gel, ethyl acetate) (4) 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-[(tetrahydrofuran-3-yl)methoxy]-quinazoline Mass spectrum (ESI'): m/z = 417, 419 [M-H]"
Rf value: 0.41 (silica gel, ethyl acetate) (5) 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-[(tetrahydropyran-4-yl)methoxy]-quinazoline Mass spectrum (ESI+): mlz = 433, 435 [M+H]+

Rf value: 0.79 (silica gel, ethyl acetate/methanol = 9:1) (6) 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI+): m/z = 419, 421 [M+H]' Rf value: 0.44 (silica gel, ethyl acetate) (7) 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI`): m/z = 419, 421 [M+H]+
Rf value: 0.44 (silica gel, ethyl acetate) Example V

(R)-N-[(tetrahydrofuran-2-yl)methyl]-N-methyl-amine 21.10 g of (R)-N-[(tetrahydrofuran-2-yl)methyl]-N-benzyl-N-methyl-amine (crude product from Example VI) are dissolved in 200 ml of methanol and hydrogenated in the presence of 4.00 g of palladium on activated charcoal (10 % Pd) at ambient temperature until the uptake of hydrogen has ended. For working up the catalyst is filtered off and the filtrate is evaporated using the rotary evaporator. A thin yellow oil is left, which is further reacted without any more purification.
Yield: 8.60 g (73 % of theory) Mass spectrum (ESI+): m/z = 116 [M+H]+

The following compounds are obtained analogously to Example V:
(1) (S)-N-[(tetrahydrofuran-2-yl)methyl]-N-methyl-amine Mass spectrum (ESI'): m/z = 116 [M+H]+

(2) N-[(tetrahydropyran-4-yl)methyl]-N-methyl-amine Mass spectrum (ESI`): m/z = 130 [M+H]+

.

Example VI

(R)-N-[(tetrahydrofuran-2- rLI)methyl]-N-benzvl-N-methyl-amine A solution of 24.60 g of (R)-tetrahydrofuran-2-carboxylic acid-N-benzyl-N-methyl-amide in 90 ml tetrahydrofuran is added dropwise to 17.00 g of lithium aluminium hydride in 150 ml of tetrahydrofuran. The reaction mixture is refluxed for two hours. For working up it is cooled to 0 C in an ice bath, mixed with 20 ml of water and 10 ml of 15N sodium hydroxide solution and stirred for another 20 minutes. Then it is filtered through a layer of magnesium sulphate and washed with a total of about 500 ml of tetrahydrofuran. The filtrate is evaporated down in vacuo, leaving a yellowish oil which is further reacted without any more purification.
Yield: 21.10 g (92 % of theory) Mass spectrum (ESI'): m/z = 206 [M+H]+

The following compounds are obtained analogously to Example VI:
(1) (S)-N-[(tetrahydrofuran-2-yl)methyl]-N-benzyl-N-methyl-amine Rf value: 0.20 (silica gel, ethyl acetate/methanol = 9:1) (2) N-[(tetrahydropyran-4-yl)methyl]-N-benzyl-N-methyl-amine Mass spectrum (ESI+): m/z = 220 [M+H]+

Example VII

(R)-tetrahydrofuran-2-carboxylic acid-N-benzyl-N-methyl-amide 25.30 g of N-benzyl-N-methyl-amine are added to a solution of 20.00 ml of (R)-tetrahydrofuran-2-carboxylic acid in 200 ml tetrahydrofuran. Then a total of 67.10 g of O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate are added batchwise while cooling with an ice bath and the reaction mixture is then stirred for about 48 h at ambient temperature. The precipitate formed is suction filtered, the filtrate is evaporated, mixed with water and filtered again. The filtrate obtained is made alkaline with sodium hydrogen carbonate solution and extracted with ethyl acetate. The combined ethyl acetate extracts are washed with water and saturated sodium chloride solution, dried over magnesium sulphate and evaporated down. A yellowish oil remains, which is further reacted without any more purification.
Yield: 24.60 g (54 % of theory) Mass spectrum (ESI'): m/z = 220 [M+H]+
Rf value: 0.62 (silica gel, ethyl acetate) The following compounds are obtained analogously to Example VII:
(1) (S)-tetrahydrofuran-2-carboxylic acid-N-benzyl-N-methyl-amide Mass spectrum (ESI`): m/z = 242 [M+Na]' Rf value: 0.62 (silica gel, ethyl acetate) (2) tetrahydropyran-4-carboxylic acid-N-benzyl-N-methyl-amide (The amide coupling is carried out with 1,1'-carbonyidiimidazole in tetrahydrofuran.) Mass spectrum (ESI+): m/z = 256 [M+Na]+
Rf value: 0.45 (silica gel, ethyl acetate) Example VIII

6-Amino-4-((3-chloro-4-fluorophenyl)amino]-7-[(tetrahydropyran-4-yl)methoxyl-Quinazoline 22.80 g of 4-[(3-chloro-4-fiuorophenyl)amino]-6-nitro-7-[(tetrahydropyran-4-yl)methoxy]-quinazoline are hydrogenated in 300 ml of tetrahydrofuran in the presence of 3.50 g of platinum dioxide at ambient temperature until the calculated amount of hydrogen has been taken up. The catalyst is filtered off and the filtrate is evaporated to dryness using the rotary evaporator. The residue is stirred with diethylether, suction filtered, washed with diethylether and dried at ambient temperature.
Yield: 19.95 g(93 % of theory) Mass spectrum (ESI+): m/z = 403, 405 [M+H]+
Melting point: 221 C

The following compounds are obtained analogously to Example VIII:

(1) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI''): m/z = 389, 391 [M+H]+
Rf value: 0.11 (silica gel, ethyl acetate) (2) 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI+): mlz = 389, 391 [M+H]+
Rf value: 0.33 (silica gel, ethyl acetate/methanol = 9:1) Preparation of the final compounds:
Example 1 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}am ino)-7-cyclopropylmethoxy-auinazoline 4.70 ml of oxalyl chloride are added dropwise to a solution of 4.50 g of bromocrotonic acid in 60 ml of methylene chloride. Then one drop of N,N-dimethylformamide is added.
After about 30 minutes the development of gas has ended and the reaction mixture is evaporated using the rotary evaporator. The crude bromocrotonic acid chloride is taken up in 30 ml of methylene chloride and, while cooling with an ice bath, added dropwise to a solution of 7.00 g of 4-[(3-chloro-4-fluorophenyl)amino]-6-amino-7-cyclopropylmethoxy-quinazoline and 10.20 ml of Hunig base in 150 ml of tetrahydrofuran. The reaction mixture is stirred for about 1.5 hours while cooling with an ice bath and then for another two hours at ambient temperature. Then 5.20 g of N-(2-methoxy-ethyl)-N-methyl-amine are added and the reaction mixture is stirred overnight at ambient temperature. For working up it is diluted with methylene chloride and washed thoroughly with water. The organic phase is dried over magnesium sulphate and evaporated down. The crude product is purified by chromatography over a silica gel column with ethyl acetate followed by ethyl acetate/methanol (19:1) as eluant.
Yield: 5.07 g (51 % of theory) Mass spectrum (ESI"): m/z = 512, 514 [M-H]' Rf value: 0.25 (silica gel, ethyl acetate/methanol = 9:1) The following compounds are obtained analogously to Example 1:

(1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclobutyloxy-quinazoline Mass spectrum (ESI"): m/z = 468, 470 [M-H]"
3 5 Rf value: 0.09 (silica gel, ethyl acetate/methanol = 9:1) (2) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline Mass spectrum (ESI"): m/z = 482, 484 [M-H]"
Rf value: 0.11 (silica gel, ethyl acetate/methanol = 9:1) (3) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(N,N-bis-(2-methoxy-ethyl)-amino)-1-oxo-2-buten-l-yl]amino}-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI"): m/z = 532 [M-H]"
1 o Rf value: 0.40 (silica gel, ethyl acetate/methanol = 9:1) (4) 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-ethyl-amino]-1-oxo-2-buten-l-yl}amino)-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI"): m/z = 502 [M-H]' Rf value: 0.20 (silica gel, ethyl acetate/methanol = 9:1) (5) 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI'): m/z = 488 [M-H]' 2 0 Rf value: 0.25 (silica gel, ethyl acetate/methanol = 9:1) (6) 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI"): m/z = 514 [M-H]"
2 5 Rf value: 0.15 (silica gel, ethyl acetate/methanol = 9:1) (7) 4-[(R)-(1-phenyl-ethyl)amino]-6-({4-[N-(tetrahydrofuran-3-yl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI-): m/z = 500 [M-H]"
3 0 Rf value: 0.18 (silica gel, ethyl acetate/methanol = 9:1) (8) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{N-[(tetrahydrofuran-3-yl)methyl]-N-methyl-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI-): m/z = 538, 540 [M-H]-3 5 Rf value: 0.27 (silica gel, ethyl acetate/methanol = 9:1) (9) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yI]amino}-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline Mass spectrum (ESI+): m/z = 486, 488 [M+H]+
(10) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylarnino)-1-oxo-2-buten-l-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline Mass spectrum (ESI+): m/z = 486, 488 [M+H]+
Rf value: 0.45 (silica gel, methylene chloride/methanol = 5:1) (11) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dirnethylamino)-1-oxo-2-buten-1-YI]amino}-7-(tetrahYdroPYran-4-YloxY)-quinazoline Mass spectrum (ESI+): m/z = 500, 502 [M+H]+
Rf value: 0.55 (silica gel, methylene chloride/methanol = 5:1) (12) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N, N-dirnethylamino)-1-oxo-2-buten-l-yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI+): m/z = 500, 502 [M+H]+
Rf value: 0.60 (silica gel, methylene chloride/methanol = 5:1) (13) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylarnino)-1-oxo-2-buten-l-yl]amino}-7-[(tetrahydrofuran-3-yl)methoxy]-quinazoline Mass spectrum (ESI'): m/z = 500, 502 [M+H]+
Rf value: 0.50 (silica gel, methylene chloride/methanol = 5:1) (14) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahydrofuran-3-yl)methoxy]-quinazoline Mass spectrum (ESI+): mlz = 528, 530 [M+H]+
Rf value: 0.31 (silica gel, ethyl acetate/methanol = 9:1) (15) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI`): mlz = 446 [M+H]+
Rf value: 0.11 (silica gel, ethyl acetate/methanol = 9:1) (16) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N,N-bis-(2-methoxy-ethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI'): m/z = 588, 590 [M+H]`
Rf value: 0.55 (silica gel, methylene chloride/methanol = 9:1) (17) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahyd rofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI+): m/z = 542, 544 [M+H]+
Rf value: 0.55 (silica gel, methylene chloride/methanol = 9:1).
(18) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N-(2-methoxy-ethyl)-N-methyl-amino]-1-oxo-2-buten-1-yl}amino)-7-cyclopentyloxy-quinazoline Mass spectrum (ESI+): m/z = 528, 530 [M+H]+
Rf value: 0.25 (silica gel, ethyl acetate/methanol = 9:1) (19) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{(R)-N-[(tetrahydrofuran-2-yl)methyl]-N-methyl-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI+): m/z = 540, 542 [M+H]+
Melting point: 149-153 C
(20) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{(S)-N-[(tetrahydrofuran-2-yl)methyl]-N-methyl-amino}-1-oxo-2-buten-1-yl)am ino]-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI+): m/z = 540, 542 [M+H]+
Rf value: 0.29 (silica gel, ethyl acetate/methanol = 9:1) (21) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline Mass spectrum (ESI+): m/z = 560 [M+H]+
Rf value: 0.17 (silica gel, ethyl acetate/methanol = 9:1) (22) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopentyloxy-quinazoline Mass spectrum (ESI'): m/z = 508, 510 [M-H]"
Melting point: 140 C

(23) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-cyclopropyl-N-methyl-amino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI+): m/z = 496, 498 [M+H]+
Rf value: 0.42 (silica gel, ethyl acetate/methanol = 9:1) (24) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{N-[(tetrahydropyran-4-yl)methyl]-N-methyl-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI+): m/z = 554, 556 [M+H]+
Melting point: 141 C
(25) 4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-{N-[(tetrahydropyran-4-yl)methyl]-N-methyl-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline Mass spectrum (ESI+): m/z = 530 [M+H]+
Rf value: 0.32 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:0.5) (26) 4-[(3-chloro-4-fluorophenyl)arnino]-6-[(4-{(R)-N-[(tetrahydrofuran-2-yl)methyl]-N-methyl-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopentyloxy-quinazoline Mass spectrum (ESI+): m/z = 554, 556 [M+H]+
Melting point: 117-121 C
(27) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{(S)-N-[(tetrahydrofuran-2-yl)methyl]-N-methyl-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopentyloxy-quinazoline Mass spectrum (ESI`): m/z = 554, 556 [M+H]+
Rf value: 0.32 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:0.5) (28) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dirnethylamino)-1-oxo-2-buten-l-yl]amino}-7-[(tetrahydropyran-4-yl)methoxy]-quinazoline Mass spectrum (ESI+): m/z = 514, 516 [M+H]+
Rf value: 0.19 (silica gel, methylene chloride/methanol/conc. aqueous ammonia = 95:5:0.05) (29) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahydropyran-4-yl)methoxy]-quinazoline Mass spectrum (ESI"): m/z = 554, 556 [M-H]-Melting point: 174 C

(30) 4-[(3-chloro-4-fluorophenyl)amino]-6-({4-[N,N-bis-(2-methoxy-ethyl)-amino]-1-oxo-2-buten-1-yl}amino)-7-[(tetrahydropyran-4-yl)methoxy]-quinazoline Mass spectrum (ESI+): m/z = 602, 604 [M+H]+
Melting point: 100-102 C
(31) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-buten-l-yl]amino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI+): m/z = 500, 502 [M+H]+
Melting point: 110-112 C
(32) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-l-yl]arnino}-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI+): m/z = 500, 502 [M+H]+
Rf value: 0.23 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:0.1) (33) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-ethyl-N-methyl-amino)-1-oxo-2-buten-l-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline Mass spectrum (ESI+): m/z = 500, 502 [M+H]+
Melting point: 154-157 C
(34) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-isopropyl-N-methyl-amino)-1-oxo-2-buten-l-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline Mass spectrum (ESI+): m/z = 514, 516 [M+H]+
Rf value: 0.34 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) (35) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline Mass spectrum (ESI'): m/z = 528, 530 [M+H]+
Melting point: 184-185 C
(36) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-isopropyl-N-methyl-amino)-1-oxo-2-buten-l-yl]amino}-7-cyclopentyloxy-quinazoline Mass spectrum (ESI+): m/z = 512, 514 [M+H]+
Rf value: 0.53 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:0.5) (37) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-ethyl-N-methyl-amino)-1-oxo-2-buten-l-yl]amino}-7-[(S.)-(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI-): m/z = 512, 514 [M-H]-Rf value: 0.15 (silica gel, ethyl acetate/methanol/conc. aqueous ammonia =
90:10:1) (38) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI-): m/z = 526, 528 [M-H]"
Rf value: 0.27 (silica gel, methylene chloride/methanol = 9:1) (39) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N-isopropyl-N-methyl-amino)-1-oxo-2-buten-l-yl]amino}-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline Mass spectrum (ESI+): m/z = 528, 530 [M+H]`
Rf value: 0.31 (silica gel, methylene chloride/methanol = 9:1).
The following compounds may also be prepared analogously to the foregoing Examples and other methods known from the literature:

(1) 4-benzylamino-6-{[4-(N,N-diethylamino)-1-oxo-2-buten-1-yl]amino}-7-cyclopropyl-methoxy-quinazoline (2) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-{N-[(tetrahydropyran-4-yl)methyl]-N-methyl-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline (3) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahydropyran-4-yl) methoxy]-quinazoline (4) 4-[(R)-(1-phenyl-ethyl)amino]-6-[(4-{N-[(tetrahydrofuran-2-yl)methyl]-N-methyl-amino}-1-oxo-2-buten-1-yl)amino]-7-cyclopropylmethoxy-quinazoline (5) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-l-yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline (6) 4-[(R)-(1-phenyi-ethyl)amino]-6-({4-[N,N-bis-(2-methoxy-ethyl)-amino]-1-oxo-2-buten-l-3 5 yl}amino)-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline =

(7) 4-[(R)-(1-phenyl-ethyl)amino]-6-{[4-(morpholin-4-yl)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline Example 2 Coated tablets containing 75 mg of active substance 1 tablet core contains:
active substance 75.0 mg calcium phosphate 93.0 mg corn starch 35.5 mg polyvinylpyrrolidone 10.0 mg hydroxypropylmethylcellulose 15.0 mg is magnesium stearate 1.5 mg 230.0 mg Preparation:
The active substance is mixed with calcium phosphate, corn starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose and half the specified amount of magnesium stearate. Blanks 13 mm in diameter are produced in a tablet-making machine and these are then rubbed through a screen with a mesh size of 1.5 mm using a suitable machine and mixed with the rest of the magnesium stearate. This granulate is compressed in a tablet-making machine to form tablets of the desired shape.
Weight of core: 230 mg die: 9 mm, convex The tablet cores thus produced are coated with a film consisting essentially of hydroxypropylmethylcellulose. The finished film-coated tablets are polished with beeswax.
Weight of coated tablet: 245 mg.

Exampfe 3 Tablets containing 100 mg of active substance Composition:
1 tablet contains:
active substance 100.0 mg lactose 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg magnesium stearate 2.0 mg 220.0 mg Method of Preparation:
The active substance, lactose and starch are mixed together and uniformly moistened with an aqueous solution of the polyvinylpyrrolidone. After the moist composition has been screened (2.0 mm mesh size) and dried in a rack-type drier at 50 C it is screened again (1.5 mm mesh size) and the lubricant is added. The finished mixture is compressed to form tablets.
Weight of tablet: 220 mg Diameter: 10 mm, biplanar, facetted on both sides and notched on one side.
Example 4 Tablets containing 150 mg of active substance Composition:
1 tablet contains:
active substance 150.0 mg powdered lactose 89.0 mg corn starch 40.0 mg collpidal silica 10.0 mg polyvinylpyrrolidone 10.0 mg magnesium stearate 1.0 mg 300.0 mg Preparation:

The active substance mixed with lactose, corn starch and silica is moistened with a 20%
aqueous polyvinylpyrrolidone solution and passed through a screen with a mesh size of 1.5 mm. The granules, dried at 45 C, are passed through the same screen again and mixed with the specified amount of magnesium stearate. Tablets are pressed from the mixture.
Weight of tablet: 300 mg die: 10 mm, flat Example 5 Hard gelatine capsules containing 150 mg of active substance 1 capsule contains:
active substance 50.0 mg corn starch (dried) approx. 80.0 mg lactose (powdered) approx. 87.0 mg magnesium stearate 3.0 mg approx. 420.0 mg Preparation:

The active substance is mixed with the excipients, passed through a screen with a mesh size of 0.75 mm and homogeneously mixed using a suitable apparatus. The finished mixture is packed into size 1 hard gelatine capsules.
Capsule filling: approx. 320 mg Capsule shell: size 1 hard gelatine capsule.

Example 6 Suppositories containing 150 mg of active substance 1 suppository contains:
active substance 150.0 mg polyethyleneglycol 1500 550.0 mg polyethyleneglycol 6000 460.0 mg polyoxyethylene sorbitan monostearate 840.0 mg 2,000.0 mg Preparation:

After the suppository mass has been melted the active substance is homogeneously i5 distributed therein and the melt is poured into chilled moulds.

Example 7 Suspension containing 50 mg of active substance 100 ml of suspension contain:
active substance 1.00 g carboxymethylcellulose-Na-salt 0.10 g rriethyl p-hydroxybenzoate 0.05 g propyl p-hydroxybenzoate 0.01 g glucose 10.00 g glycerol 5.00 g 70% sorbitol solution 20.00 g flavouring 0.30 g dist. water ad 100 ml Preparation:

The distilled water is heated to 70 C. The methyl and propyl p-hydroxybenzoates together with the glycerol and sodium salt of carboxymethylcellulose are dissolved therein with stirring.

The solution is cooled to ambient temperature and the active substance is added and homogeneously dispersed therein with stirring. After the sugar, the sorbitol solution and the flavouring have been added and dissolved, the suspension is evacuated with stirring to eliminate air.
5 ml of suspension contain 50 mg of active substance.
Example 8 Ampoules containing 10 mg active substance Composition:
active substance 10.0 mg 0.01 N hydrochloric acid q.s.
double-distilled water ad 2.0 ml Preparation:
The active substance is dissolved in the requisite amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 2 ml ampoules.
Example 9 Ampoules containing 50 mg of active substance Composition:
active substance 50.0 mg 0.01 N hydrochloric acid q.s.
double-distilled water ad 10.0 ml Preparation:
The active substance is dissolved in the necessary amount of 0.01 N HCI, made isotonic with common salt, filtered sterile and transferred into 10 ml ampoules.

Example 10 Capsules for powder inhalation containing 5 mg of active substance 1 capsule contains:

active substance 5.0 mg lactose for inhalation 15.0 mg 20.0 mg Preparation:
The active substance is mixed with lactose for inhalation. The mixture is packed into capsules in a capsule-making machine (weight of the empty capsule approx. 50 mg).
weight of capsule: 70.0 mg size of capsule 3 Example 11 Solution for inhalation for hand-held nebulisers containing 2.5 mg active substance 1 spray contains:

active substance 2.500 mg benzalkonium chloride 0.001 mg 1 N hydrochloric acid q.s.
ethanol/water (50/50) ad 15.000 mg Preparation:
The active substance and benzalkonium ch-loride are dissolved in ethanol/water (50/50). The pH of the solution is adjusted with 1 N hydrochloric acid. The resulting solution is filtered and transferred into suitable containers for use in hand-held nebulisers (cartridges).

Contents of the container: 4.5 g

Claims (26)

CLAIMS:
1. A compound of general formula:

wherein R a denotes a 1-phenylethyl or a 3-chloro-4-fluorophenyl group, R b denotes a dimethylamino group and R c denotes a tetrahydrofuran-3-yl-oxy, tetrahydrofuran-2-yl-methoxy, tetrahydro-furan-3-yl-methoxy, tetrahydropyran-4-yl-oxy or tetrahydropyran-4-yl-methoxy group, or a tautomer, a stereoisomer or a salt thereof.
2. A compound, tautomer, stereoisomer or salt according to claim 1, wherein R a denotes a 3-chloro-4-fluorophenyl group, and R c denotes a tetrahydrofuran-3-yl-oxy or tetrahydropyran-4-yl-oxy group.
3. 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline; or a tautomer or salt thereof.
4. 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-l-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline; or a tautomer or salt thereof.
5. 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-(tetrahydropyran-4-yloxy)-quinazoline; or a tautomer, stereoisomer or salt thereof.
6. 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahydrofuran-2-yl)methoxy]-quinazoline; or a tautomer, stereoisomer or salt thereof.
7. 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahydrofuran-3-yl)methoxy]-quinazoline; or a tautomer, stereoisomer or salt thereof.
8. 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline; or a tautomer or salt thereof.
9. 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-quinazoline; or a tautomer or salt thereof.
10. 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-[(tetrahydropyran-4-yl)methoxy]-quinazoline; or a tautomer, stereoisomer or salt thereof.
11. 4-[(3-Chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline.
12. A physiologically acceptable salt of a compound defined in any one of claims 1 to 10 with an inorganic or organic acid or base.
13. A physiologically acceptable salt of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline.
14. A pharmaceutical composition comprising:

a compound, tautomer, stereoisomer or salt as defined in claim 1, 2, 5, 6, 7 or 10; a compound, tautomer or salt as defined in claim 3, 4, 8 or 9; a compound as defined in claim 11; or a physiologically acceptable salt as defined in claim 12 or 13; and a pharmaceutically acceptable carrier or diluent.
15. A pharmaceutical composition according to claim 14, which is in the form of a tablet.
16. A pharmaceutical composition according to claim 15, wherein the tablet is a coated tablet.
17. A pharmaceutical composition according to claim 14, 15 or 16 for use in the treatment of a benign or malignant tumor.
18. A pharmaceutical composition according to claim 14, 15 or 16 for use in the treatment or prevention of a disease of the airways or lungs.
19. A pharmaceutical composition according to claim 14, 15 or 16 for use in the treatment of a disease of one or more of the gastrointestinal tract, the bile duct and the gall bladder.
20. Use of:

a compound, tautomer, stereoisomer or salt as defined in claim 1, 2, 5, 6, 7 or 10; a compound, tautomer or salt as defined in claim 3, 4, 8 or 9; a compound as defined in claim 11; or a physiologically acceptable salt as defined in claim 12 or 13, in preparing a pharmaceutical composition for treating a benign or malignant tumour, for preventing or treating a disease of the airways and lungs or for treating a disease of one or more of the gastrointestinal tract, the bile duct and the gall bladder.
21. Use of:

a compound, tautomer, stereoisomer or salt as defined in claim 1, 2, 5, 6, 7 or 10; a compound, tautomer or salt as defined in claim 3, 4, 8 or 9; a compound as defined in claim 11; or a physiologically acceptable salt as defined in claim 12 or 13, for the treatment of a benign or malignant tumour.
22. Use of:

a compound, tautomer, stereoisomer or salt as defined in claim 1, 2, 5, 6, 7 or 10; a compound, tautomer or salt as defined in claim 3, 4, 8 or 9; a compound as defined in claim 11; or a physiologically acceptable salt as defined in claim 12 or 13, for the prevention or treatment of a disease of the airways or lungs.
23. Use of:

a compound, tautomer, stereoisomer or salt as defined in claim 1, 2, 5, 6, 7 or 10; a compound, tautomer or salt as defined in claim 3, 4, 8 or 9; a compound as defined in claim 11; or a physiologically acceptable salt as defined in claim 12 or 13, for the treatment of a disease of one or more of the gastrointestinal tract, the bile duct and the gall bladder.
24. A compound, tautomer, stereoisomer or salt as defined in claim 1, 2, 5, 6, 7 or 10; a compound, tautomer or salt as defined in claim 3, 4, 8 or 9; a compound as defined in claim 11; or a physiologically acceptable salt as defined in claim 12 or 13, for treating a benign or malignant tumour, for preventing or treating a disease of the airways and lungs or for treating a disease of one or more of the gastrointestinal tract, the bile duct and the gall bladder.
25. A process for preparing a compound as defined in claim 1, wherein:

a compound of general formula wherein R a and R c are defined as in claim 1, is reacted with a compound of general formula wherein R b is defined as in claim 1 and Z1 denotes a leaving group or a hydroxy group.
26. A process for preparing a compound as defined in claim 1, wherein a compound of general formula wherein R a and R c are defined as in claim 1 and Z2 denotes a leaving group, is reacted with a compound of general formula H-R b (V) , wherein R b is defined as in claim 1.
CA002432428A 2000-12-20 2001-12-12 Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them Expired - Lifetime CA2432428C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10063435.4 2000-12-20
DE10063435A DE10063435A1 (en) 2000-12-20 2000-12-20 Chinazoline derivatives, pharmaceuticals containing these compounds, their use and process for their preparation
PCT/EP2001/014569 WO2002050043A1 (en) 2000-12-20 2001-12-12 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof

Publications (2)

Publication Number Publication Date
CA2432428A1 CA2432428A1 (en) 2002-06-27
CA2432428C true CA2432428C (en) 2009-09-01

Family

ID=7667887

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002432428A Expired - Lifetime CA2432428C (en) 2000-12-20 2001-12-12 Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Country Status (39)

Country Link
EP (2) EP2112140A1 (en)
JP (1) JP3827641B2 (en)
KR (1) KR100852102B1 (en)
CN (1) CN1277822C (en)
AR (1) AR040524A1 (en)
AT (1) ATE430136T1 (en)
AU (2) AU1917402A (en)
BE (1) BE2014C009I2 (en)
BG (1) BG66139B1 (en)
BR (1) BRPI0116266B8 (en)
CA (1) CA2432428C (en)
CY (2) CY1109290T1 (en)
CZ (1) CZ302721B6 (en)
DE (2) DE10063435A1 (en)
DK (1) DK1345910T3 (en)
EA (1) EA006317B1 (en)
EE (1) EE05244B1 (en)
ES (1) ES2326617T3 (en)
FR (1) FR14C0009I2 (en)
HR (1) HRP20030504B1 (en)
HU (2) HU228874B1 (en)
IL (2) IL156277A0 (en)
LT (1) LTC1345910I2 (en)
LU (1) LU92370I2 (en)
ME (1) ME02777B (en)
MX (1) MXPA03005559A (en)
MY (1) MY136086A (en)
NO (3) NO325672B1 (en)
NZ (1) NZ526918A (en)
PL (1) PL214798B1 (en)
PT (1) PT1345910E (en)
RS (1) RS50860B (en)
SI (1) SI1345910T1 (en)
SK (1) SK287573B6 (en)
TW (1) TWI295992B (en)
UA (1) UA74614C2 (en)
UY (1) UY27078A1 (en)
WO (1) WO2002050043A1 (en)
ZA (1) ZA200304141B (en)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201900A3 (en) 1999-06-21 2003-02-28 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (en) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (en) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
PE20040945A1 (en) * 2003-02-05 2004-12-14 Warner Lambert Co PREPARATION OF SUBSTITUTED QUINAZOLINES
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10307165A1 (en) * 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334226A1 (en) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
DK1667991T3 (en) 2003-09-16 2008-08-18 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (en) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Process for the preparation of aminocrotonyl compounds
AU2005239878B9 (en) * 2004-05-06 2010-01-07 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
WO2006081741A1 (en) * 2005-02-05 2006-08-10 Piaoyang Sun Quinazoline compounds or their medical salts and preparation and medical usage thereof
KR100832594B1 (en) * 2005-11-08 2008-05-27 한미약품 주식회사 Quinazoline derivatives as an multiplex inhibitor and method for the preparation thereof
EP1948180B1 (en) * 2005-11-11 2013-03-13 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
CA2833852C (en) * 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
WO2007085638A1 (en) * 2006-01-26 2007-08-02 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
CA2663599A1 (en) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
WO2008095847A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
KR20100111291A (en) 2008-02-07 2010-10-14 베링거 인겔하임 인터내셔날 게엠베하 Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
EA019183B1 (en) 2008-05-13 2014-01-30 Астразенека Аб Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
PE20100252A1 (en) 2008-06-06 2010-04-12 Boehringer Ingelheim Int NEW SOLID PHARMACEUTICAL FORMULATIONS INCLUDING 4 - [(3-CHLORO-4-FLUOROPHENYL) AMINO DIMALEATE] -6 - {[4- (N, N-DIMETHYLAMINO) -1-OXO-2-BUTEN-1-IL] AMINO } -7 - ((S) -TETRAHIDROFURAN-3-ILOXI) -QUINAZOLINA
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
EP2313397B1 (en) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method
WO2010054285A2 (en) 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
WO2010130758A1 (en) * 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of cancer and fibrotic diseases
DK2451445T3 (en) 2009-07-06 2019-06-24 Boehringer Ingelheim Int PROCEDURE FOR DRYING BIBW2992, IT'S SALTS AND SOLID PHARMACEUTICAL FORMULATIONS INCLUDING THIS ACTIVE INGREDIENT
JP2013512882A (en) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング BIBW2992 for use in the treatment of triple negative breast cancer
US8735409B2 (en) * 2009-12-21 2014-05-27 Qiang Zhang Quinazoline derivatives
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
EP2608792B1 (en) 2010-08-26 2017-10-11 Boehringer Ingelheim International GmbH Methods of administering an egfr inhibitor
EA024026B1 (en) * 2010-11-25 2016-08-31 Рациофарм Гмбх Novel salts and polymorphic forms of afatinib
BR112013022552B1 (en) 2011-03-04 2021-11-23 Newgen Therapeutics, Inc QUINAZOLINE COMPOUNDS REPLACED WITH ALCINE, THEIR USE, PHARMACEUTICAL COMPOSITION, AND KIT
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
WO2012155339A1 (en) * 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-phenylamino-6-butenamide-7-alkyloxy quinazoline derivatives, preparative method and use thereof
CN102838590B (en) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 Amino quinazoline derivative and application thereof in preparation of antineoplastic drugs
EP2753616A1 (en) 2011-10-06 2014-07-16 Ratiopharm GmbH Crystalline forms of afatinib di-maleate
CN103073539B (en) * 2011-10-26 2016-05-11 齐鲁制药有限公司 4-(substituted benzene amino) quinazoline derivant and preparation method thereof, pharmaceutical composition and purposes
UA111010C2 (en) 2012-01-17 2016-03-10 Астеллас Фарма Інк. PIRASINCARBOXAMID COMPOUND
CN103772380A (en) * 2012-10-23 2014-05-07 杨子娇 Type of compounds for treating narrow chamber angle and use of compounds
US20150368230A1 (en) 2013-02-01 2015-12-24 Boehringer Ingelheim International Gmbh Radiolabeled quinazoline derivatives
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (en) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 Therapeutic uses of empagliflozin
HRP20190101T1 (en) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh THERAPEUTIC USES OF EMPAGLIFLOZINE
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1215378A1 (en) 2013-04-18 2016-08-26 勃林格殷格翰国际有限公司 Pharmaceutical composition, methods for treating and uses thereof
CN103254183B (en) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 Ah method is for the preparation method of Buddhist nun
CN103254182A (en) * 2013-05-10 2013-08-21 苏州明锐医药科技有限公司 Method for preparing Afatinib
WO2014180271A1 (en) * 2013-05-10 2014-11-13 苏州明锐医药科技有限公司 Method for preparing afatinib and intermediate thereof
WO2014183560A1 (en) * 2013-05-16 2014-11-20 苏州明锐医药科技有限公司 Afatinib and preparation method of intermediate thereof
CN103242303B (en) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 Afatinib preparation method
CN104513229A (en) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 Quinazoline derivatives and preparation method thereof
CN103755688B (en) * 2013-12-24 2015-11-18 江苏奥赛康药业股份有限公司 A kind of Ah method is for the preparation method of Buddhist nun's compound
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
EP3089976B1 (en) 2014-01-02 2019-08-14 Teva Pharmaceuticals International GmbH Crystalline forms of afatinib dimaleate
CN105315263B (en) * 2014-07-30 2018-11-27 正大天晴药业集团股份有限公司 The synthetic method of afatinib intermediate
EP3023421A1 (en) 2014-11-21 2016-05-25 Sandoz Ag Crystalline forms of afatinib dimaleate
CN105801568B (en) 2015-01-15 2019-07-30 杭州普晒医药科技有限公司 One maleate crystal form of Afatinib and preparation method thereof and pharmaceutical composition
ES2775614T3 (en) 2015-03-20 2020-07-27 Chai Tai Tianqing Pharmaceutical Group Co Ltd Quinazoline derivative salts and method of preparation thereof
CN105175400B (en) * 2015-09-29 2018-04-10 河北神威药业有限公司 A kind of preparation method of afatinib intermediate
WO2017141271A1 (en) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical composition of afatinib
CN106442793B (en) * 2016-10-21 2019-05-24 河北神威药业有限公司 A kind of detection method of the intermediate for preparing Afatinib and its enantiomter
US20180125813A1 (en) 2016-11-10 2018-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TWI808958B (en) 2017-01-25 2023-07-21 美商特普醫葯公司 Combination therapy involving diaryl macrocyclic compounds
WO2019126136A2 (en) * 2017-12-18 2019-06-27 Sterngreene, Inc. Pyrimidine compounds useful as tyrosine kinase inhibitors
CN110437163A (en) * 2018-05-03 2019-11-12 斯特恩格林公司 Pyrimidines as tyrosine kinase inhibitor
WO2020068867A1 (en) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
CN109265449B (en) * 2018-11-07 2021-11-23 沈阳工业大学 EGFR and HER2 double-target tyrosine kinase inhibitor and preparation method and application thereof
AU2019407426A1 (en) 2018-12-21 2021-07-22 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN109824657A (en) * 2019-03-26 2019-05-31 石药集团中奇制药技术（石家庄）有限公司 Two maleic acid Afatinib novel crystal forms of one kind and its preparation method and application
BR112022002518A2 (en) 2019-08-15 2022-07-19 Black Diamond Therapeutics Inc ALKYNYL QUINAZOLINE COMPOUNDS
CN110590682A (en) * 2019-10-14 2019-12-20 重庆医科大学 A kind of method for preparing Afatinib impurity and prepared impurity
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN114980883A (en) 2020-01-20 2022-08-30 阿斯利康(瑞典)有限公司 Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TWI847289B (en) * 2021-09-30 2024-07-01 大陸商北京賽特明強醫藥科技有限公司 Quinazoline compounds, compositions and applications thereof
JP2025510910A (en) 2022-03-31 2025-04-15 アストラゼネカ・アクチエボラーグ EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AKT INHIBITORS FOR THE TREATMENT OF CANCER - Patent application
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20250214995A1 (en) 2022-04-28 2025-07-03 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3370340B2 (en) * 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー Irreversible inhibitors of tyrosine kinase
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
DE19908567A1 (en) * 1999-02-27 2000-08-31 Boehringer Ingelheim Pharma New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
DE19911366A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma New 4-amino-quinazoline or quinoline derivatives, are tyrosine kinase-mediated signal transduction inhibitors useful e.g. for treating tumors, polyps or respiratory or gastrointestinal diseases
HUP0301132A3 (en) * 1999-02-27 2004-03-29 Boehringer Ingelheim Pharma 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases, process for their preparation their use and pharmaceutical compositions containing them
DE19911509A1 (en) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
HUP0201900A3 (en) * 1999-06-21 2003-02-28 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof
DE50111799D1 (en) * 2000-04-08 2007-02-15 Boehringer Ingelheim Pharma BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
KR20030071787A (en) 2003-09-06
CY1109290T1 (en) 2014-07-02
YU49603A (en) 2006-05-25
IL156277A (en) 2009-12-24
MY136086A (en) 2008-08-29
UA74614C2 (en) 2006-01-16
UY27078A1 (en) 2002-07-31
NO325672B1 (en) 2008-07-07
AU2002219174B2 (en) 2007-09-06
CN1481370A (en) 2004-03-10
EE05244B1 (en) 2009-12-15
MEP59508A (en) 2011-05-10
HRP20030504A2 (en) 2005-06-30
BG66139B1 (en) 2011-07-29
CZ302721B6 (en) 2011-09-21
DE10063435A1 (en) 2002-07-04
ES2326617T3 (en) 2009-10-16
SK7712003A3 (en) 2003-10-07
EP1345910B1 (en) 2009-04-29
PT1345910E (en) 2009-07-14
BE2014C009I2 (en) 2021-02-04
CY2014008I2 (en) 2015-12-09
AR040524A1 (en) 2005-04-13
DK1345910T3 (en) 2009-07-20
NO20032726L (en) 2003-06-16
NO2022028I1 (en) 2022-07-01
ZA200304141B (en) 2004-04-15
IL156277A0 (en) 2004-01-04
EE200300300A (en) 2003-10-15
BG107929A (en) 2005-01-31
LTC1345910I2 (en) 2022-06-10
EP1345910A1 (en) 2003-09-24
JP2004516283A (en) 2004-06-03
EP1345910B9 (en) 2014-06-04
EA006317B1 (en) 2005-10-27
HRP20030504B1 (en) 2011-09-30
CY2014008I1 (en) 2014-07-02
JP3827641B2 (en) 2006-09-27
TWI295992B (en) 2008-04-21
BRPI0116266B8 (en) 2021-07-27
NO2014003I2 (en) 2015-10-19
HUP0301852A2 (en) 2003-09-29
BRPI0116266B1 (en) 2017-10-31
NO20032726D0 (en) 2003-06-16
LU92370I9 (en) 2019-01-17
FR14C0009I1 (en) 2014-03-07
HK1060571A1 (en) 2004-08-13
PL361798A1 (en) 2004-10-04
CA2432428A1 (en) 2002-06-27
SI1345910T1 (en) 2009-08-31
SK287573B6 (en) 2011-03-04
EA200300671A1 (en) 2004-06-24
AU1917402A (en) 2002-07-01
PL214798B1 (en) 2013-09-30
HUP0301852A3 (en) 2008-03-28
NO2014003I1 (en) 2014-06-02
RS50860B (en) 2010-08-31
FR14C0009I2 (en) 2014-11-14
WO2002050043A1 (en) 2002-06-27
ME02777B (en) 2011-10-10
DE50114874D1 (en) 2009-06-10
NZ526918A (en) 2006-11-30
LU92370I2 (en) 2014-03-31
HU228874B1 (en) 2013-06-28
HUS1400005I1 (en) 2017-08-28
EP2112140A1 (en) 2009-10-28
CN1277822C (en) 2006-10-04
BR0116266A (en) 2004-02-17
KR100852102B1 (en) 2008-08-13
CZ20031930A3 (en) 2003-10-15
LTPA2014005I1 (en) 2022-05-25
ATE430136T1 (en) 2009-05-15
ES2326617T9 (en) 2014-09-10
MXPA03005559A (en) 2004-10-14

Similar Documents

Publication Publication Date Title
CA2432428C (en) Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
USRE43431E1 (en) Quinazoline derivatives and pharmaceutical compositions containing them
AU775285B2 (en) Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
AU2001287694B2 (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
US6656946B2 (en) Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US20040044014A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
CA2484395C (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US20060264450A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20070185081A1 (en) Bicyclic heterocylces, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2516426A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2417955A1 (en) Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20211213